The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Blinatumomab Effective in Phase II Ph+ ALL Study
July 17th 2015Monotherapy with blinatumomab has demonstrated promising complete remission (CR) or CR with partial hematological recovery (CRh) rates in adult patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia.
Everolimus Activity Linked With PIK3CA/PTEN Status in HER2-Positive Breast Cancer
July 16th 2015PIK3CA mutations and low/no expression of PTEN correlated with an extension in progression-free survival for patients with metastatic HER2-positive breast cancer treated with the combination of everolimus, trastuzumab, and paclitaxel.
Atezolizumab Achieves Primary Endpoint in Pivotal Phase II Bladder Cancer Study
July 13th 2015Second-line treatment with atezolizumab (MPDL3280A) has met the primary endpoint of a pivotal phase II study by effectively shrinking tumors in patients with locally advanced or metastatic urothelial bladder cancer.
Adding Atezolizumab to Chemotherapy Shows Promise in NSCLC
July 10th 2015Stephen Liu, MD, discusses the results and purpose of the uniquely designed trial examining atezolizumab in combination with platinum-based doublet chemotherapy in treatment-naïve patients with advanced non–small cell lung cancer.
FDA Extends Cobimetinib Review Period in Advanced Melanoma
July 1st 2015The FDA has extended the review period for the MEK inhibitor cobimetinib in combination with the BRAF inhibitor vemurafenib (Zelboraf) for patients with BRAFV600 mutation-positive advanced melanoma by 3 months, making the new decision date November 11, 2015.
OncLive® Welcomes Sarah Cannon Cancer Network to Strategic Alliance Partnership Program
July 1st 2015OncLive® will team with Sarah Cannon, the global cancer enterprise of Hospital Corporation of America, as it further expands its Strategic Alliance Partnership Program for raising awareness of cancer treatment and research.